Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 12/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062949 | 1.00 | KEAP1 (1.00) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL418664 | 1.00 | KEAP1 (1.00) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL16713396 | 0.98 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL2764243 | 0.98 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL198312 | 0.98 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL1235433 | 0.98 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL198082 | 0.98 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL3909615 | 0.98 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7269393 | 0.98 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL29903954 | 0.98 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 699 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302975-A1 | METHODS AND COMPOSITIONS FOR AGONISING TLR3 | UNITED STATES GOVERNMENT | 2025-10-02 | — | — | US | claimed |
| US-12358908-B2 | Crystals, preparation method and application of a muscarinic receptor antagonist | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2025-07-15 | — | — | US | claimed |
| EP-3842419-B1 | METHOD OF MAKING THREO GLYCOPYRROLATE TOSYLATE | JOURNEY MEDICAL CORP (US) | 2024-04-03 | — | — | EP | claimed |
| CN-113461585-B | Synthesis process of glycopyrronium bromide | 安徽普利药业有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-116208351-A | Malicious node detection framework for resisting CPMA attack in Internet of things | 南京航空航天大学 | 2023-06-02 | — | — | CN | claimed |
| US-20230167107-A1 | CRYSTALS, PREPARATION METHOD AND APPLICATION OF A MUSCARINIC RECEPTOR ANTAGONIST | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2023-06-01 | — | — | US | claimed |
| CN-106769697-B | Real-time tracking and measuring device and method for thermodynamic properties of atmospheric nanoparticles | 北京大学 | 2023-05-16 | — | — | CN | claimed |
| EP-4144733-A1 | CRYSTAL OF M RECEPTOR ANTAGONIST AS WELL AS PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Beijing Showby Pharmaceutical Co., Ltd. (CN) | 2023-03-08 | — | — | EP | claimed |
| US-11542232-B2 | Process for production of glycopyrronium tosylate | JOURNEY MEDICAL CORPORATION (US) | 2023-01-03 | — | — | US | claimed |
| CN-115397823-A | M receptor antagonist crystal, preparation method and application thereof | 北京硕佰医药科技有限责任公司 | 2022-11-25 | — | — | CN | claimed |
| CN-1673209-A | Active metabolic product of phencynonate and its medicinal use | INST OF TOXICANT PHARMACOLOGY (CN) | 2005-09-28 | — | — | CN | claimed |
| US-20040072863-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2004-04-15 | — | — | US | claimed |
| EP-1353919-A2 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2003-10-22 | — | — | EP | claimed |
| EP-0734724-B1 | PROCESS FOR THE PREPARATION OF A PHENCYNONATE HYDROCHLORIDE OF ALPHA-CONFIGURATION | INST PHARM & TOXICOLOGY AMMS (CN) | 2003-08-20 | — | — | EP | claimed |
| WO-2002053564-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2002-07-11 | — | — | WO | claimed |
| US-6028198-A | CATALYTIC ESTERIFICATION OF 3-METHYL AZABICYCLO (3, 3, 1) NONAN-9 ALPHA-OL WITH METHYL OR ETHYL 2-PHENYL-2-CYCLOPENTYL-2-HYDROXY-ACETATE OR 2-PHENYL-2-CYCLOPENTYL-2-HYDROXY-ACETIC ACID | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY SCIENCES P.L.A. (CN) | 2000-02-22 | — | — | US | claimed |
| CN-1045956-C | Method for preparing benzene ring nonyl ester | INST OF POISON & MEDICINE ACAD (CN) | 1999-10-27 | — | — | CN | claimed |
| CN-1182738-A | Method for preparing benzene ring nonyl ester | INST OF POISON AND MEDICINE MI (CN) | 1998-05-27 | — | — | CN | claimed |
| EP-0734724-A1 | A COMPOSITION FOR PREVENTING AND TREATING KINETOTIA SYNDROME | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. (CN) | 1996-10-02 | — | — | EP | claimed |
| CN-1089838-A | Pharmaceutical composition for preventing and treating motion sickness syndrome | INST OF POISON MATERIAL MEDICA (CN) | 1994-07-27 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167107-A1 | CRYSTALS, PREPARATION METHOD AND APPLICATION OF A MUSCARINIC RECEPTOR ANTAGONIST | CHRM5, CHRM2, CHRM3 | KEAP1 4502/4885NFE2L2 4008/4885CHRM3 3/4885 |
| US-20040072863-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | CYP11B1, CYP3A7, CBR1 | KEAP1 1020/4885NFE2L2 901/4885CHRM3 26/4885 |
| US-12358908-B2 | Crystals, preparation method and application of a muscarinic receptor antagonist | CHRM5, CHRM2, CHRM3 | KEAP1 4502/4885NFE2L2 4008/4885CHRM3 3/4885 |
| US-11542232-B2 | Process for production of glycopyrronium tosylate | TPO, GYPA, THRA | KEAP1 4660/4885NFE2L2 4800/4885CHRM3 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.